Genenta Science S.p.A (GNTA) Accounts Payables (2020 - 2025)
Genenta Science S.p.A (GNTA) posted Accounts Payables of $1.8 million for Q4 2025, up 54.67% sequentially from $1.1 million in Q2 2025, and up 417.28% YoY from $339631.7 in Q4 2024.
Genenta Science S.p.A (GNTA) Accounts Payables (2020 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Accounts Payables for 6 years, with the latest figure at $1.8 million in Q4 2025.
- Quarterly Accounts Payables rose 417.28% year-over-year to $1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.8 million (up 417.28% YoY) and the FY2025 annual result came in at $1.8 million, up 417.28% from the prior year.
- Accounts Payables climbed to $1.8 million in Q4 2025 per GNTA's latest filing, from $1.1 million in the prior quarter.
- Over five years, Accounts Payables peaked at $1.8 million in Q4 2025 and troughed at $188548.1 in Q4 2021.
- A 5-year average of $653702.9 and a median of $380333.0 in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2021 and 2022: Accounts Payables plunged 70.98% in 2021, then jumped 463.86% in 2022.
- Over 5 years, Accounts Payables stood at $188548.1 in 2021, then soared by 463.86% to $1.1 million in 2022, then plunged by 70.15% to $317375.4 in 2023, then increased by 7.01% to $339631.7 in 2024, then soared by 417.28% to $1.8 million in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.8 million, $1.1 million, and $339631.7 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - | 1.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.76 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Dec 31, 2024 | 339,631.68 |
| Jun 30, 2024 | 437,050.52 |
| Dec 31, 2023 | 317,375.37 |
| Jun 30, 2023 | 380,332.98 |
| Dec 31, 2022 | 1.06 Mn |
| Jun 30, 2022 | 264,535.09 |
| Dec 31, 2021 | 188,548.15 |
| Dec 31, 2020 | 649,783.66 |